Walvax Biotechnology Co., Ltd.
300142
Κατάταξη σε μετοχές
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Τιμή μετοχής
$1.87
Κεφαλαιοποίηση
$2.98B
Αλλαγή (1 ημέρα)
-3.71%
Αλλαγή (1 έτος)
14.73%
Χώρα
CN
Εμπόριο Walvax Biotechnology Co., Ltd. (300142)
Κατηγορία
Healthcare
Έσοδα για την Walvax Biotechnology Co., Ltd. (300142)
Έσοδα τον Jun 2026 TTM: $313.01M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Walvax Biotechnology Co., Ltd., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $313.01M. Το 2024, η εταιρεία είχε έσοδα $386.55M μείωση σε σύγκριση με τα έσοδα του έτους 2023, τα οποία ήταν $581.16M. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Walvax Biotechnology Co., Ltd. από 2007 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $313.01M | -9.14% |
| 2025 | $344.50M | -10.88% |
| 2024 | $386.55M | -33.49% |
| 2023 | $581.16M | -21.19% |
| 2022 | $737.39M | 35.35% |
| 2021 | $544.82M | 21.10% |
| 2020 | $449.89M | 179.41% |
| 2019 | $161.02M | 26.68% |
| 2018 | $127.11M | 23.75% |
| 2017 | $102.71M | 20.66% |
| 2016 | $85.12M | -45.05% |
| 2015 | $154.92M | 33.46% |
| 2014 | $116.08M | 20.76% |
| 2013 | $96.13M | 11.51% |
| 2012 | $86.20M | 15.58% |
| 2011 | $74.58M | 37.20% |
| 2010 | $54.36M | 55.20% |
| 2009 | $35.03M | 29.85% |
| 2008 | $26.97M | 52.25% |
| 2007 | $17.72M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $23.54B | 7,419.13% |
DE
|
|
| $23.73B | 7,482.90% |
DE
|
|
| $29.24B | 9,241.55% |
JP
|
|
| $5.85B | 1,768.57% |
CH
|
|
| $6.34B | 1,926.24% |
IN
|
